Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Non-Hodgkin's Lymphoma Low Grade.
Latest Information Update: 17 Apr 2019
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 11 Dec 2017 Status changed from active, no longer recruiting to discontinued.
- 18 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Apr 2008 The expected completion date for this trial is now 1 Dec 2011 according to ClinicalTrials.gov.